Evidence map›Paper›PMID 40027700›Full record

ArticlebioRxiv : the preprint server for biology2025

Design, development, and evaluation of gene therapeutics specific to KSHV-associated diseases.

Tomoki Inagaki, Jonna Espera, Kang-Hsin Wang, Somayeh Komaki, Sonali Nair, Ryan R Davis, Ashish Kumar, Ken-Ichi Nakajima, Yoshihiro Izumiya

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Tomoki InagakiDepartment of Dermatology, School of Medicine, the University of California Davis (UC Davis), Sacramento, California, USA.ORCID 0009-0007-2332-9895
Jonna EsperaDepartment of Dermatology, School of Medicine, the University of California Davis (UC Davis), Sacramento, California, USA.
Kang-Hsin WangDepartment of Dermatology, School of Medicine, the University of California Davis (UC Davis), Sacramento, California, USA.
Somayeh KomakiDepartment of Dermatology, School of Medicine, the University of California Davis (UC Davis), Sacramento, California, USA.
Sonali NairDepartment of Dermatology, School of Medicine, the University of California Davis (UC Davis), Sacramento, California, USA.
Ryan R DavisDepartment of Pathology and Laboratory Medicine, School of Medicine, UC Davis, Sacramento, California, USA.
Ashish KumarDepartment of Dermatology, School of Medicine, the University of California Davis (UC Davis), Sacramento, California, USA.
Ken-Ichi NakajimaDepartment of Dermatology, School of Medicine, the University of California Davis (UC Davis), Sacramento, California, USA.
Yoshihiro IzumiyaDepartment of Dermatology, School of Medicine, the University of California Davis (UC Davis), Sacramento, California, USA.ORCID 0000-0002-9184-2603

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
Studies on Epigenetically Active Latent Chromatin MaintenanceR01AI167663 · NIAID · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Yoshihiro Izumiya · 2022 to 2026
$2.6M
Studies on Viral Enhancer for Latency-Lytic SwitchR01CA290700 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Yoshihiro Izumiya · 2025 to 2026
$1.1M
Characterization of KSHV-Associated Disease Specific Gene TherapyR21CA299587 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Yoshihiro Izumiya · 2025 to 2026
$414k
NCI NIH HHS P30 CA093373NCI NIH HHS R01 CA290700NCI NIH HHS R21 CA299587NIAID NIH HHS R01 AI167663
6 · The paper itself

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi's sarcoma (KS) and two human lymphoproliferative diseases: primary effusion lymphoma and AIDS-related multicentric Castleman's disease. KSHV-encoded latency-associated nuclear antigen (LANA) is expressed in KSHV-infected cancer cells and is responsible for maintaining viral genomes in infected cells. Thus, LANA is an attractive target for therapeutic intervention for KSHV-associated diseases. Here, we devised a cancer gene therapy vector using the adeno-associated virus (AAV), which capitalizes the LANA's function to maintain terminal repeat (TR) containing circular genome in latently infected cells and the TR's enhancer function for KSHV inducible gene promoters. By including two TR copies with a lytic inducible gene promoter (TR2-

Identifiers

PMID40027700
PMCPMC11870588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.